Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Taku Okazaki"'
Autor:
Tomoya Katakai, Taku Okazaki
Publikováno v:
Biophysics and Physicobiology, Vol 21 (2024)
In a post-growth multicellular organism, the phenomenon in which a small number of rare cells can be the starting point for inducing a dramatic change in the entire system is considered a “biological singularity.” The immune response and cancer c
Externí odkaz:
https://doaj.org/article/0f605ceee1524ff392e9ee103392eec0
Autor:
Taku Okazaki, Tomoya Katakai
Publikováno v:
Biophysics and Physicobiology, Vol 21 (2024)
Externí odkaz:
https://doaj.org/article/a986dbc4977b43c78423adf42bae06e9
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
To prevent the destruction of tissues owing to excessive and/or inappropriate immune responses, immune cells are under strict check by various regulatory mechanisms at multiple points. Inhibitory coreceptors, including programmed cell death 1 (PD-1)
Externí odkaz:
https://doaj.org/article/950de31b1ac94cbfa1aec9f714d117d7
Autor:
Reina Mizuno, Daisuke Sugiura, Kenji Shimizu, Takumi Maruhashi, Mizuki Watada, Il-mi Okazaki, Taku Okazaki
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Cancer-immunotherapy targeting programmed cell death 1 (PD-1) activates tumor-specific T cells and provides clinical benefits in various cancers. However, the molecular basis of PD-1 function is still enigmatic. Especially, it is unclear which signal
Externí odkaz:
https://doaj.org/article/c0d7da358b534ea39efc29d64154b03a
Autor:
Taku OKAZAKI1
Publikováno v:
Information Bulletin of the Union of National Economic Associations in Japan. 2023, Issue 43, p8-13. 6p.
Autor:
Jianshi Jin, Taisaku Ogawa, Nozomi Hojo, Kirill Kryukov, Kenji Shimizu, Tomokatsu Ikawa, Tadashi Imanishi, Taku Okazaki, Katsuyuki Shiroguchi
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 120(1)
Single-cell whole-transcriptome analysis is the gold standard approach to identifying molecularly defined cell phenotypes. However, this approach cannot be used for dynamics measurements such as live-cell imaging. Here, we developed a multifunctional
Publikováno v:
International Immunology. 33:693-698
Cancer immunotherapies that target PD-1 (programmed cell death 1) aim to destroy tumors by activating tumor-specific T cells that are otherwise inactivated by PD-1. Although these therapies have significantly improved the outcomes of patients with di
Autor:
Jehanne Hassan, Elizabeth Appleton, Bahire Kalfaoglu, Malin Pedersen, José Almeida-Santos, Hisashi Kanemaru, Nobuko Irie, Shane Foo, Omnia Reda, Benjy J.Y. Tan, Il-mi Okazaki, Taku Okazaki, Yorifumi Satou, Kevin Harrington, Alan Melcher, Masahiro Ono
The blockade of the immune checkpoints PD-1 and CTLA-4 enhances T cell response. However, it is largely unknown how antigen-reactive T cells regulate their checkpoint expression in vivo and whether and how the checkpoint blockade can change activatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db8cb1d9af3e601a3c1d0591c82c161e
https://doi.org/10.1101/2022.07.19.500582
https://doi.org/10.1101/2022.07.19.500582
Publikováno v:
Cancers, Vol 13, Iss 4616, p 4616 (2021)
Cancers
Cancers
Simple Summary Immune checkpoint blockade (ICB) therapies are attracting much attention for the clinical treatment of tumors. Combination therapies are being developed to enhance the effects of ICBs, and the importance of tumor-draining lymph nodes (
Autor:
Jianshi Jin, Taisaku Ogawa, Nozomi Hojo, Kirill Kryukov, Kenji Shimizu, Tomokatsu Ikawa, Tadashi Imanishi, Taku Okazaki, Katsuyuki Shiroguchi
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America; 1/3/2023, Vol. 120 Issue 1, p1-9, 61p